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Abstract 
The aim of this study is to improve the solubility of poorly water soluble drug Nisoldipine by formulating 
the solid dispersion with different water soluble carriers. This will improve the dissolution rate of 
antihypertensive drug, Nisoldipine. For this purpose, polyvinyl pyrrolidone (PVP) k-25and polyethylene 
glycol (PEG) 4000 were used as carriers and dispersion was carried out by solvent evaporation technique. 
Formulations were characterized by particle size analysis, fourier transform infrared spectroscopy (FTIR), 
differential scanning calorimetry (DSC), drug content determination and dissolution studies. The particle 
size was found in range of 43.52 - 45.12 μm. FTIR studies showed the compatibility between drug and 
polymers. DSC study indicated that the drug was in amorphous form which results in better dissolution of 
the drug from the solid dispersion as compared to the pure drug and physical mixture. Dissolution studies 
indicated better release for solid dispersions and solubility was also increased 15 folds than pure drug. This 
could provide the formulation technology with a potential of increased bioavailability of poorly water 
soluble drug by increasing its dissolution rate.      
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1. Introduction 
The bioavailability of poorly water soluble drugs is the main focus of research these days. For this purpose, 
numbers of technologies are developed including solid dispersion technique (Chiou and Riegelman, 1971; 
Leuner and Dressman, 2000; Ryan et al., 2005). The solid dispersion technique resulted in improved 
bioavailability of many drugs which are now commercially available (Sethia and Squillante, 2003). In this 
technique, drug crystals are very finely divided and dispersed in water soluble carrier. Many carries are 
used in this formulation technique but mainly polyvinyl pyrrolidone (Hirasawa et al., 2003) and 
polyethylene glycol (Verheyen et al., 2002) can easily be utilized. Many methods are employed for the 
formulation of solid dispersions but solvent evaporation technique offer more potential and circumvents the 
difficulties faced in other methods. Nisoldipine, an anti-hypertensive drug, is a calcium channel blocking 
agent included in dihydropyridine family. Nisoldipine is 
(9/)3-isobutyl-5-methyl-1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-pyridine-3,5-dicarboxylate. It is 
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mainly indicated for hypertension, angina pectoris and heart failure (Vogt and Kreuzer, 1983). This drug 
has poor water solubility and high hepatic metabolism. Nisoldipine is Class II drug of Biopharmaceutical 
system (BCS) with low bioavailability. This makes nisoldipine a potential drug of choice for solid 
dispersion formulation which will result in improved solubility, dissolution and ultimately bioavailability. 
Solid dispersions of nisoldipine were characterized by particles size analysis, fourier transform infrared 
spectroscopy (FTIR) and differential scanning calorimetry (DSC). Drug content determination and 
dissolution studies were carried out for further analysis. 
2. Materials and Methods 
2.1. Materials 
Nisoldipine was purchased from Sigma Chemical Co. (USA). Polyvinyl pyrrolidone k-25 (PVP k-25) was 
purchased from Riedel-deHaen. Sodium lauryl sulphate (SLS) and Polyethylene glycol 4000 (PEG 4000) 
was purchased from Merck. All other chemicals and reagents used were of analytical grade. 
2.2. Method 
Nisoldipine is a light sensitive drug so all the experiments were carried out in light protected environment. 
2.2.1. Preparation of physical mixtures 
Physical mixtures were prepared by mixing of Nisoldipine and polymers in mortar and pestle by 
geometrical dilution method. This mixture is then passed through sieve (335 μm) (Six et al., 2004). All 
physical mixtures were prepared by same process and their composition is shown in table 1. 
2.2.2. Preparation of solid dispersions 
Solid dispersions were prepared by solvent evaporation method. The composition of all formulations is 
presented in table 1. Polyvinyl pyrrolidone k-25 and polyethylene glycol 4000 were dissolved in ethanol 
with continuous stirring until clear solution is obtained. Nisoldipine was then added to above said mixture 
with continuous stirring for 45 minutes. The solvent was removed under reduced pressure and the resulting 
solid dispersions were kept at room temperature in a dessicator, whch is then subjected to pulverization and 
sieving (Lingam and Venkateswarlu, 2009). 
Table 1: Composition of formulations of physical mixtures (PM) and solid dispersions (SD) 
Formulation Nisoldipine PVP k-25  PEG 4000 
PM1    1  2  
PM2    1  4  
PM3    1  6  
PM4    1     2 
PM5    1     4 
PM6    1     6 
SD1    1  2  
SD2    1  4  
SD3    1  6  
SD4    1     2 
SD5    1     4 
SD6    1     6 
2.3. Characterization of Nisoldipine solid dispersions 
2.3.1. Particle size analysis 
Particle size analysis was carried out by laser diffraction size analyzer (LS 13 320, Beckman Coulter, CA). 
For this purpose, the samples were ultrasonicated for a minute after suspending in silicone oil. Then these 
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samples were analysed by laser diffraction analyser. 
2.3.2. FTIR spectroscopy 
The FTIR spectra for all the formulations were collected on FTIR spectrometer Pristige-21 (Shimadzu- 
Japan). KBr discs were prepared by mixing the samples with potassium bromide before analysis. Samples 
were analyzed over the range of 4000-400 cm-1 at the resolution of 2 cm-1.  
2.3.3. Differential scanning calorimetry (DSC) 
DSC was performed for pure drug, polymers and all the formulations using DSC (DT-60, Shimadzu, Japan). 
Samples equivalent to 4-5mg of drug were sealed in aluminum pans and then heated. Temperature range 
was 50-300 0C at a rate of 20 0C per minute. 
2.3.4. X-ray powder diffraction (XRD) 
X-ray diffraction of nisoldipine and the formulations was carried out by diffractometer. This was done to 
determine the polymorphic state of nisoldipine. Recording was made form 3 to 1500 in Si (Li) PSD 
detector with scanning speed of 30 per minute. All the process was operated at 40kV and 35mA. 
2.3.5. Drug content determination 
All the samples of various formulations were placed in 25 ml volumetric flask (equivalent to 20 mg of 
drug). 10 ml methanol was added to the each sample mixture and sonicated for 10 minutes. Methanol was 
used to make the final volume. This solution is then diluted by methanol up to certain extent so that it can 
easily be analyzed spectrophotometrically at λ = 238 nm (Swami et al., 2010). 
2.3.6. Dissolution studies 
Dissolution studies were performed using Type II paddle apparatus. The dissolution medium consisted of 
900 ml phosphate buffer solution with pH 6.8 containing 1 % sodium lauryl sulphate (SLS). The 
temperature was maintained at 37 ± 0.5 ˚C and stirring speed of 60 rpm. 
Samples (equivalent to 10 mg of nisoldipine) were spread on the surface of dissolution medium. 5 ml of 
aliquots were withdrawn at specific intervals and measured spectorphotometrically for nisoldipine content 
at wavelength 238 nm. The volume of dissolution medium was kept constant by adding same amount of 
fresh medium. 
Drug dissolution was determined by plotting a graph between drug dissolved and time interval. 
2.3.7. Solubility studies 
Solubility studies were carried out for pure nisoldipine and all the formulations by placing them in medium 
of pH 6.8. All the samples were shaken for 48 hours in an orbital shaker by keeping temperature at 37 ˚C. 
This solution is then filtered by whatmann filter paper and filtrate was further diluted and measured 
spectrophotometrically at 238 nm 
3. Results and Discussion 
3.1. Particle size analysis 
Particles size analysis was carried out for all the solid dispersion formulations as it plays an important role 
in drug release. Smaller the size more will be the release. The particle size for all solid dispersion 
formulations was found to be in range of 43.52 - 45.12 μm as shown in table 2 
3.2. FTIR spectroscopy 
FTIR spectroscopy was carried out for determination of any polymorphic alteration in complexes and to 
check interaction between drug and polymers. FTIR of pure nisoldipine showed characteristic peaks at 
wave number 3320 cm-1 indicating N-H stretching. Peak at 3001 cm-1 indicated C-H stretching and peak 
at 1701 cm-1 showed the presence of C=O stretch. There was also peak at 1555 cm-1 indicated the 
presence of nitro group and at 1230 cm-1 for ether absorption. 
All the formulations i.e. physical mixtures and solid dispersions showed principle peaks of nisoldipine but 
the peak at 3320 cm-1 of N-H stretching was not observed in case of solid dispersion of nisoldipine with 
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both PVP k-25 and PEG 4000 showing functional group interaction between drug and polymer. All other 
peaks were observed with less intensity. The spectra of solid dispersions with polymers showed all the 
characteristic peaks but with less intensity than pure nisoldipine as shown in Fig.1. 
Table 2: Particle size analysis of solid dispersion formulations 
     Formulation    Particle Size (μm) 
     SD1      43.52 
     SD2      43.96 
     SD3      44.69 
     SD4      43.72 
     SD5      44.56 
     SD6      45.12 
 
Fig: 1. FTIR Spectra of A: Nisoldipine, B: PVP k-25, C: PEG 4000, D: PM3, E: PM6, F: SD3, G: SD6 
3.3. Differential scanning calorimetry (DSC) 
DSC was carried out for thermal analysis of drug and polymer after formulation. This is very helpful tool in 
evaluation of physicochemical properties of drug. All thermal curves are shown in Fig. 2. Pure nisoldipine 
showed a sharp endothermic peak at 151 oC (Melting point range of Nisoldipine = 150-155 oC). Thermal 
Peak of PVP k25 was at 112 oC and that of PEG 4000 was at 55 oC. The thermograms of all the 
formulations showed peaks shifted to slightly lower melting point as shown in Fig. 2. This can be attributed 
to change in physical state of nisoldipine from crystal to amorphous during the preparation of solid 
dispersion. As amorphous state has high disorder and high energy state so the solid dispersions had 
enhanced solubility and higher dissolution rates. 
3.4. X-ray powder diffraction (XRD) 
XRD studies were carried out for confirmation of results obtained from DSC studies to evaluate the 
physicochemical properties of active drug. The XRD of pure nisoldipine showed sharp peaks whereas the 
diffractogram of the complex showed reduction in peak intensity as shown in Fig. 3. 
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Fig: 2. DSC of A: Nisoldipine, B: PVP k-25, C: PEG 4000, D: PM3, E: PM6, F: SD3, G: SD6 
 
Fig 3. XRD of A: Nisoldipine, B: Complex 
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3.5. Drug content determination 
Drug content determination was carried out for control of drug quality and effectiveness of process for 
preparation of formulation. The drug content of various formulations was in range of 79.9 to 87.5 % w/w. 
The results confirmed the homogeneous distribution of drug within complexes.  
3.6. Dissolution studies 
Dissolution studies were carried out to determine the release properties of drug from the formulations. 
Dissolution rates can be increased by reducing particle size and absence of crystallinity of drug. Table 3 and 
Fig. 4 showed the dissolution profile of pure nisoldipine, physical mixture and solid dispersion prepared by 
PVP k25 and table 4 and Fig. 5 showed the dissolution profile of formulations using PEG 4000 as polymer. 
Solid dispersion complex showed maximum dissolution rates in 90 minutes followed by the dissolution rate 
of physical mixtures and pure nisoldipine in formulations of both polymers. 
Increased dissolution rates for physical mixtures can be attributed to increased surface area of drug and 
solubility of drug when come in contact with dissolution medium as carrier dissolves resulting in enhanced 
wettability of drug (Liu et al., 2006). In case of solid dispersion complexes, increased dissolution rates can 
be attributed to reduced particle size and reduction in crystallinity resulting in increased wettability 
(Muralidhar et al., 2011; Sharma and Jain, 2010). Reduction in crystallinity was also confirmed by DSC 
studies. 
Overall result of dissolution studies showed that PVP had improved drug release than PEG 4000 for 
nisoldipine solid dispersion. These results were in accordance with Lingam and Venkateswarlu, (2009). 
Table 3: Dissolution Study of various formulations by PVP k-25 
Sr. No. Time (min) NSD  PM1 PM2 PM3 SD1  SD2  SD3 
1  0   0  0  0  0  0  0  0 
2  15   6.3  8.3  9.1  9.8  18.3  19.9  20.5 
3  30   17.8  19.1  20.8  21.3  36.9  37.5  38.4 
4  45   29.1  32.6  33.4  35.2  55.4  56.1  57.8 
5  60   43.6  47.2  48.5  49.7  68.8  69.7  71.3 
6  75   58.2  64.3  66.1  66.3  79.2  80.6  83.1 
7  90   61.5  72.8  74.1  74.6  87.8  92.1  94.6 
 
Fig 4. Dissolution of Pure Nisoldipine, PM and SD with PVP k-25 
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Table 4: Dissolution Study of various formulations by PEG 4000 
Sr. No. Time (min) NSD  PM4 PM5 PM6 SD4  SD5  SD6 
1  0   0  0  0  0  0  0  0 
2  15   6.3  7.4  8.2  9.8  17.2  18.7  19.3 
3  30   17.8  18.2  19.6  24.6  35.3  36.5  38.7 
4  45   29.1  30.9  31.4  39.2  54.6  55.8  58.6 
5  60   43.6  45.7  46.8  51.4  67.9  69.1  72.2 
6  75   58.2  62.8  64.1  66.3  76.8  78.9  83.1 
7  90   61.5  70.6  72.3  74.8  81.3  86.7  88.1 
 
Fig 5. Dissolution of Pure Nisoldipine, PM and SD with PEG 4000 
3.7. Solubility studies 
Solubility studies were carried out to estimate the bioavailability of the drug. The solubility of pure 
nisoldipine was found to be 0.0246 mg/ml but after its formulation in solid dispersion complex the 
solubility of nisoldipine increased about 15 folds. The pH solubility profile of nisoldipine does not alter 
over the pH range of 1-8 which proved that the solubility of nisodipine is independent to pH..  
 
Fig 6. pH Solubility Profile of Nisoldipine 
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4. Conclusion 
Solid dispersion of nisoldipine was prepared by solvent evaporation method, a simple and easily 
reproducible method. The evaluation of all the formulations was carried out by various parameters. FTIR 
studies showed the adequate behavior of drug. DSC and XRD studies showed reduction in crystallinity of 
nisoldipine. Drug content was also found to be adequate. Dissolution was carried out with all the 
formulations and SD3 showed highest release and found to be the best formulation. Solubility of 
nisoldipine was also increased to 15 folds in solid dispersion formulation. Therefore, it can be assessed that 
improvement in dissolution rate of hydrophobic nisoldipine was achieved. 
These formulations can also be used further for buccal tablets to avoid systemic metabolism but this 
formulation provided a potential for increased bioavailability of drug to the body. 
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